Growth differentiating factor-15 (GDF-15): A potential biomarker and therapeutic target for cancer-associated weight loss
Growth differentiating factor-15 (GDF-15): A potential biomarker and therapeutic target for cancer-associated weight loss
复制标题
DOI：
10.3892/ol.2016.5183
复制
发表时间：
2016-11-01
期刊：
影响因子：
2.9
通讯作者：
Jatoi, Aminah
中科院分区：
文献类型：
--
作者：
Lerner, Lorena;Gyuris, Jeno;Jatoi, Aminah
生长分化因子-15 (GDF-15)，也被称为巨噬细胞抑制因子-1，是转化生长因子超家族的一员，与癌症相关的体重减轻有关。本研究调查了转移性肺癌或外分泌胰腺癌患者的癌症相关体重减轻与血浆GDF-15浓度以及其他生物标志物之间的关系。在1年的时间里，共有218名患者入组。患者队列包括152例无法治愈的肺癌患者和66例无法治愈的胰腺癌患者。在218例患者中，98例（45%）报告在诊断前6个月内体重减轻了5%，62例（28%）报告体重减轻了5%，58例（27%）报告没有体重减轻。在肺癌患者中，较高的循环GDF-15水平与体重减轻显著相关；报告体重减轻5%的肺癌患者（n=56）的GDF-15循环浓度是体重没有减轻的肺癌患者（n=48）的两倍
Growth differentiating factor-15 (GDF-15), also known as macrophage inhibiting factor-1, is a member of the transforming growth factor- superfamily, which has been implicated in cancer-associated weight loss. The present study investigated the association between cancer-associated weight loss and plasma GDF-15 concentration, as well as other biomarkers, in patients with metastatic lung or exocrine pancreatic cancer. A total of 218 patients were enrolled over a 1-year period. The patient cohort included 152 patients with incurable lung cancer and 66 patients with incurable pancreatic cancer. Of the 218 patients, 98 (45%) reported >5% weight loss, 62 (28%) reported 5% weight loss and 58 (27%) reported no weight loss in the 6 months prior to diagnosis. In lung cancer patients, higher circulating GDF-15 levels were significantly associated with weight loss; lung cancer patients who reported >5% weight loss (n=56) were found to exhibit twice the circulating concentration of GDF-15 compared with those that exhibited no weight loss (n=48) (P